Zanamivir | CAS#139110-80-8 | neuraminidase inhibitor

MedKoo Cat#: 318993 | Name: Zanamivir

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Zanamivir is a neuraminidase inhibitor used in the treatment and prophylaxis of influenza caused by influenza A and B viruses. It was developed by the Australian biotech firm Biota Holdings. It was licensed to Glaxo in 1990 and approved in the US in 1999, only for use as a treatment for influenza. In 2006, it was approved for prevention of influenza A and B. Zanamivir was the first neuraminidase inhibitor commercially developed. Zanamivir works by binding to the active site of the neuraminidase protein, rendering the influenza virus unable to escape its host cell and infect others.[14] It is also an inhibitor of influenza virus replication in vitro and in vivo.

Chemical Structure

Zanamivir

CAS#139110-80-8 (free base)

Theoretical Analysis

MedKoo Cat#: 318993

Name: Zanamivir

CAS#: 139110-80-8 (free base)

Chemical Formula: C12H20N4O7

Exact Mass: 332.1332

Molecular Weight: 332.31

Elemental Analysis: C, 43.37; H, 6.07; N, 16.86; O, 33.70

Price and Availability

Size	Price	Availability	Quantity
5mg	USD 300.00
10mg	USD 450.00
25mg	USD 700.00

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

139110-80-8 (free base) 551942-41-7 (hydrate)

Synonym

GR-121167X; GR121167X; GR 121167X; GG167; GG-167; GG 167; Zanamivir; trade name Relenza.

IUPAC/Chemical Name

(2R,3R,4S)-3-acetamido-4-(diaminomethylideneamino)-2-[(1R,2R)-1,2,3-trihydroxypropyl]-3,4-dihydro-2H-pyran-6-carboxylic acid

InChi Key

ARAIBEBZBOPLMB-UFGQHTETSA-N

InChi Code

InChI=1S/C12H20N4O7/c1-4(18)15-8-5(16-12(13)14)2-7(11(21)22)23-10(8)9(20)6(19)3-17/h2,5-6,8-10,17,19-20H,3H2,1H3,(H,15,18)(H,21,22)(H4,13,14,16)/t5-,6+,8+,9+,10+/m0/s1

SMILES Code

O=C(C1=C[C@H](/N=C(N)\N)[C@@H](NC(C)=O)[C@H]([C@H](O)[C@H](O)CO)O1)O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO, not in water

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Certificate of Analysis

View CoA: current batch, Lot#C20M01C27

Safety Data Sheet (SDS)

View Safety Data Sheet (SDS)

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 332.31 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Guan Z, Tian D, Wang M, Meng X, Kang J, Hu Z, Xu H, Ma X, Jin T, Gao X, Zhang Y, Gu Y, Liu X, Chen X. Zanamivir alleviates ethanol intoxication through activating catalase. Toxicol Lett. 2025 Feb 21;406:40-49. doi: 10.1016/j.toxlet.2025.02.010. Epub ahead of print. PMID: 39988212. 2: El-Deeb IM, von Itzstein M. A Simple and Efficient Stereoselective Synthesis of a 2,3-Difluorosialic Acid-Based Influenza Virus Neuraminidase Inhibitor. Chemistry. 2025 Jan 16:e202404342. doi: 10.1002/chem.202404342. Epub ahead of print. PMID: 39817632. 3: Miyairi I, Miyazawa S, Takahashi Y, Kojima S, Kitanishi Y, Ogura E. Incidence of severe illness in pediatric influenza outpatients treated with baloxavir or neuraminidase inhibitors. J Infect Chemother. 2025 Jan 7;31(3):102606. doi: 10.1016/j.jiac.2025.102606. Epub ahead of print. PMID: 39788370. 4: Comparison chart: Antiviral drugs for seasonal influenza for 2024-2025. Med Lett Drugs Ther. 2024 Dec 9;66(1717):e1-e5. doi: 10.58347/tml.2024.1717d. PMID: 39752725. 5: Antiviral drugs for seasonal influenza for 2024-2025. Med Lett Drugs Ther. 2024 Dec 9;66(1717):193-198. doi: 10.58347/tml.2024.1717a. PMID: 39752722. 6: Menéndez-Arias L, Gago F. Antiviral Agents: Structural Basis of Action and Rational Design. Subcell Biochem. 2024;105:745-784. doi: 10.1007/978-3-031-65187-8_20. PMID: 39738962. 7: Goto T, Kawai N, Bando T, Sato T, Tani N, Chong Y, Ikematsu H. In vitro neuraminidase inhibitory concentrations (IC50) of four neuraminidase inhibitors in the Japanese 2023-24 season: Comparison with the 2010-11 to 2022-23 seasons. J Infect Chemother. 2024 Dec 26;31(3):102602. doi: 10.1016/j.jiac.2024.102602. Epub ahead of print. PMID: 39732192. 8: Sato M. Pharmacologic background and clinical issue of anti-influenza drugs. Fukushima J Med Sci. 2025 Jan 18;71(1):1-12. doi: 10.5387/fms.24-00029. Epub 2024 Dec 18. PMID: 39694499; PMCID: PMC11799661. 9: Nakagawa N, Ono R, Odanaka K, Ohara H, Kisara S, Ito K. A Pharmacoeconomic Study of Post-Exposure Prophylaxis Strategies for Influenza Virus Infections in Japan. Adv Ther. 2025 Feb;42(2):772-787. doi: 10.1007/s12325-024-02988-6. Epub 2024 Dec 5. PMID: 39636568. 10: Scherger SJ, Kalil AC. In persons exposed to influenza, zanamivir, oseltamivir, laninamivir, and baloxavir reduce symptomatic seasonal influenza. Ann Intern Med. 2024 Dec;177(12):JC134. doi: 10.7326/ANNALS-24-03197-JC. Epub 2024 Dec 3. PMID: 39622061. 11: Sriwilaijaroen N, Hanamatsu H, Yokota I, Nishikaze T, Ijichi T, Takahashi T, Sakoda Y, Furukawa JI, Suzuki Y. Edible bird's nest: N- and O-glycan analysis and synergistic anti-avian influenza virus activity with neuraminidase inhibitors. Antiviral Res. 2024 Dec;232:106040. doi: 10.1016/j.antiviral.2024.106040. Epub 2024 Nov 20. PMID: 39577572. 12: Goto T, Kawai N, Bando T, Takasaki Y, Shindo S, Sato T, Tani N, Chong Y, Ikematsu H. Virological and Clinical Outcomes of Influenza Outpatients Treated With Baloxavir, Oseltamivir, or Laninamivir in the 2023-2024 Season. Influenza Other Respir Viruses. 2024 Nov;18(11):e70042. doi: 10.1111/irv.70042. PMID: 39557155; PMCID: PMC11573420. 13: Aldhaeefi M, Rungkitwattanakul D, Saltani I, Muirhead A, Ruehman AJ, Hawkins WA, Daftary MN. Update and narrative review of avian influenza (H5N1) infection in adult patients. Pharmacotherapy. 2024 Nov;44(11):870-879. doi: 10.1002/phar.4621. Epub 2024 Nov 16. PMID: 39548738. 14: Panthi S, Hong JY, Satange R, Yu CC, Li LY, Hou MH. Antiviral drug development by targeting RNA binding site, oligomerization and nuclear export of influenza nucleoprotein. Int J Biol Macromol. 2024 Dec;282(Pt 4):136996. doi: 10.1016/j.ijbiomac.2024.136996. Epub 2024 Oct 31. PMID: 39486729. 15: Jallow MM, Barry MA, Ndiaye NK, Touré CT, Talla C, Kiori D, Sagne SN, Sy S, Goudiaby D, Niang MN, Diagne MM, Fall G, Loucoubar C, Dia N. Genetic and antigenic characterization of influenza A(H3N2) virus after 13 consecutive years of influenza surveillance in Senegal, 2010-2022. J Med Virol. 2024 Oct;96(10):e70010. doi: 10.1002/jmv.70010. PMID: 39443827. 16: Chen X, Zhou B, Jiang X, Zhong H, You A, Zou T, Zhou C, Liu X, Zhang Y. Drug repurposing to tackle parainfluenza 3 based on multi-similarities and network proximity analysis. Front Pharmacol. 2024 Oct 1;15:1428925. doi: 10.3389/fphar.2024.1428925. PMID: 39411066; PMCID: PMC11473393. 17: Shahriar I, Kamra M, Kanduluru AK, Campbell CL, Nguyen TH, Srinivasarao M, Low PS. Targeted recruitment of immune effector cells for rapid eradication of influenza virus infections. Proc Natl Acad Sci U S A. 2024 Oct 8;121(41):e2408469121. doi: 10.1073/pnas.2408469121. Epub 2024 Sep 30. Erratum in: Proc Natl Acad Sci U S A. 2024 Dec 3;121(49):e2422717121. doi: 10.1073/pnas.2422717121. PMID: 39348541; PMCID: PMC11474073. 18: Yang H, Zhao Y, Wei S, Yu X. Isolation of Allelochemicals from Rhododendron capitatum and Their Allelopathy on Three Perennial Herbaceous Plants. Plants (Basel). 2024 Sep 15;13(18):2585. doi: 10.3390/plants13182585. PMID: 39339560; PMCID: PMC11434890. 19: Azuma T, Usui M, Hasei T, Hayashi T. Occurrence and environmental fate of anti-influenza drugs in a subcatchment of the Yodo River Basin, Japan. Sci Total Environ. 2024 Nov 25;953:176086. doi: 10.1016/j.scitotenv.2024.176086. Epub 2024 Sep 10. PMID: 39260509. 20: Influenza vaccine for 2024-2025. Med Lett Drugs Ther. 2024 Sep 16;66(1711):145-150. doi: 10.58347/tml.2024.1711a. PMID: 39250341.